Cargando…
Conducting CNS trials during a public health emergency – Lessons learned from the COVID-19 pandemic: A joint ISCTM/ECNP working group consensus paper
A joint working group between the International Society of CNS Clinical Trials and Methodology (ISCTM) and the European College of Neuropsychopharmacology (ECNP) was formed in the latter part of 2020 to explore possible ways to mitigate the impact of Coronavirus disease-19 (COVID-19) in clinical tri...
Autores principales: | Olugemo, Kemi, Bugarski-Kirola, Dragana, Dawson, Gerard R., DiCesare, Franco, Stevanović, Dejan, Samardzic, Janko, Chatzittofis, Andreas, Moore, Raeanne, Verster, Joris C., Bhering, Lais, Vieta, Eduard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier B.V. on behalf of European College of Neuropsychopharmacology.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275769/ http://dx.doi.org/10.1016/j.nsa.2023.101129 |
Ejemplares similares
-
Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia
por: Keefe, Richard S. E., et al.
Publicado: (2016) -
From neuroscience to evidence based psychological treatments – The promise and the challenge, ECNP March 2016, Nice, France
por: Goodwin, Guy M., et al.
Publicado: (2018) -
T42. HIGH ADHERENCE TO CURRENT ANTIPSYCHOTIC AND ADJUNCTIVE PIMAVANSERIN IN THE ENHANCE STUDY, A PHASE 3 TRIAL TO EVALUATE THE TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH AN INADEQUATE RESPONSE TO ANTIPSYCHOTIC TREATMENT
por: Abbs, Brandon, et al.
Publicado: (2020) -
Effects of adjunctive pimavanserin and current antipsychotic treatment on QT interval prolongation in patients with schizophrenia
por: Bugarski-Kirola, Dragana, et al.
Publicado: (2022) -
Pimavanserin Exposure-Response Analyses in Patients With Schizophrenia: Results From the Phase 2 ADVANCE Study
por: Darwish, Mona, et al.
Publicado: (2022)